LAT2 and osteosarcoma: In OS cohorts, a locus in SLC7A8 is associated with early disease progression, and LAT2 functions as a transporter for doxorubicin; notably, low LAT2 expression in non-metastatic patients correlates with poorer survival (109), this specific immunomodulatory function has not yet been verified in osteosarcoma.